News | June 02, 2021
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The company is working closely with its six manufacturing partners in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated
